Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) Operating Margin (2016 - 2025)

Altimmune (ALT) has disclosed Operating Margin for 16 consecutive years, with 417180.0% as the latest value for Q3 2025.

  • On a quarterly basis, Operating Margin rose 7816000.0% to 417180.0% in Q3 2025 year-over-year; TTM through Sep 2025 was 452310.0%, a 23706192.0% decrease, with the full-year FY2024 number at 515860.0%, down 49334146.0% from a year prior.
  • Operating Margin was 417180.0% for Q3 2025 at Altimmune, up from 458440.0% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 732.06% in Q4 2021 to a low of 1237600.0% in Q3 2022.
  • A 5-year average of 292635.41% and a median of 254937.5% in 2022 define the central range for Operating Margin.
  • Peak YoY movement for Operating Margin: crashed -121658481bps in 2022, then soared 123137348bps in 2023.
  • Altimmune's Operating Margin stood at 732.06% in 2021, then tumbled by -12033bps to 88823.08% in 2022, then fell by -2bps to 90872.97% in 2023, then plummeted by -447bps to 497320.0% in 2024, then rose by 16bps to 417180.0% in 2025.
  • Per Business Quant, the three most recent readings for ALT's Operating Margin are 417180.0% (Q3 2025), 458440.0% (Q2 2025), and 436300.0% (Q1 2025).